Abstract
Objective
The pharmacokinetics of amikacin were studied in patients undergoing slow hemodialysis (HD).
Design
Slow HD was performed at the dialysate flow rate of 30 ml/min. After a single intravenous dose of amikacin 5 mg/kg, pharmacokinetic variables were calculated by fitting indivdual concentration-time curves to a two-compartment open model.
Patients
6 critically ill patients with renal failure were entered into the study.
Results
The volume of distribution was 0.35±0.03 l/kg. Total body clearance was 35.1±2.3 ml/min with an elimination half-life of 10.5 h. During a 10.5 h session of slow HD, the serum amikacin concentration decreased from the peak level of 21.3±1.2 mg/l to 7.2±0.9 mg/l.
Conclusion
Slow HD eliminate amikacin more efficiently than other types of slowly performed renal replacement therapy and had profound effects on the pharmacokinetics. Amikacin elimination by this approach should be taken into consideration for designing a dosage schedule during the treatment.
This is a preview of subscription content, log in via an institution to check access.
References
Ronco C (1993) Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 40:187–198
Kihara M, Ikeda Y, Shibata K, Masumori S, Fujita H, Ebira H, Toya Y, Takagi N, Shionoiri H, Umemura S, Ishii M (1994) Slow hemodialysis performed during the day in managing renal failure in critically ill patients. Nephron 67:36–41
Kihara M, Ikeda Y, Shibata K, Masumori S, Ebira H, Shiratori K, Ueda S, Takagi N, Umemura S, Shionoiri H, Ishii M (1994) Pharmacokinetic profiles of intravenous imipenem/cilastatin, during slow hemodialysis in critically ill patients. Clin Nephrol (in press)
Kihara M, Ikeda Y, Shiratori K, Fujita H, Masumori S, Shibata K, Ebira H (1994) A serial application study on twice daily dose of imipenem/cilastatin in patients undergoing slow hemodialysis. Nephron (in press)
Price KE, Pursiano TA, DeFuria MD, Wright GE (1973) Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics. Antimicrob Agents Chemother 5:143–152
Konishi K, Suzuki H, Saruta T, Hayashi M, Deguchi N, Tazaki H, Hisaka A (1991) Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. Antimicrob Agents Chemother 35:1616–1620
Garraffo R, Drugeon HB, Dellamonica P, Bernard E, Lapalus P (1990) Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother 34:614–621
Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE (1976) Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay. J Infect Dis 134:S323–S330
Reguer L, Colding H, Jensen H, Kampmann JP (1977) Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrob Agents Chemother 11:214–218
Lanao JM, Dominguez-Gil A, Tabernero JM, Macias JF (1983) Influence of type of dialyzer on the pharmacokinetics of amikacin. Int J Clin Pharmacol Ther Toxicol 21:197–202
Takagi N, Oda H, Tokita Y, Yabana M, Toya Y, Abe Y, Ueda S, Minamisawa K, Yamada Y, Ishigami T, Gotoh T, Takeda K, Ishii M (1989) Changes of the serum amikacin (AMK) level in patients with serious acute renal failure treated by continuous arteriovenous hemofiltration (CAVH). Artif Organs 13:238–241
Armendariz E, Chelluri L, Ptachcinski R (1990) Pharmacokinetics of amikacin during continuous venovenous hemofiltration. Critical Care Med 18:675–676
Buring JE, Evans DA, Mayrent SL, Rosner B, Colton T, Hennekens CH (1988) Randomized trials of aminoglycoside antibiotics: quantitative overview. Rev Infect Dis 10:951–957
Kovarik JM, Hoepelman IM, Veroef J (1989) Once-daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microb Infect Dis 8:761–769
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kihara, M., Ikeda, Y., Takagi, N. et al. Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis. Intensive Care Med 21, 348–351 (1995). https://doi.org/10.1007/BF01705414
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01705414